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Syzygium polyanthum (Wight) Walp. var. polyanthum leaves are consumed as a traditional Malay treatment of hypertension. This
study investigates hypotensive potential of aqueous (AESP) and residual methanolic (met-AESP) extracts of S. polyanthum leaves
and possible involvement of autonomic receptors. AESP and met-AESP (20 to 100mg/kg) were intravenously administered into
anaesthetized Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats. Blood pressure and heart were monitored for
20min. AESP and met-AESP induced significant dose-dependent hypotension, but only 100mg/kg AESP caused mild bradycardia
(𝑛 = 5). AESP-induced hypotension was more potent than that of met-AESP in WKY. AESP has a faster onset time than
that of met-AESP in both WKY and SHR. However, met-AESP-induced hypotension was more sustained than that of AESP in
SHR. Blockages of autonomic ganglion and 𝛼-adrenergic receptors using hexamethonium and phentolamine (𝑛 = 5 for each
group) partially attenuated AESP-induced hypotension, suggesting involvement of 𝛼-adrenergic receptors. Blockages of autonomic
ganglion, 𝛽-adrenergic, cholinergic receptors, and nitric oxide production using hexamethonium, propranolol, atropine, and N-
𝜔-nitro-l arginine methyl ester (L-NAME) (𝑛 = 5 for each group) partially attenuated met-AESP-induced hypotension, suggesting
involvement of 𝛽-adrenergic and cholinergic receptors via nitric oxide production.
1. Introduction
Syzygium polyanthum (Wight) walp. var. polyanthum, or
known as “serai kayu” or “salam,” is consumed by Malays as
a traditional remedy for hypertension. S. polyanthum leaves
are well-known as traditionalmedication for various illnesses
such as cataract, diarrhoea, gastritis, hypercholesterolemia,
skin diseases, and diabetes mellitus [1]. Besides medicinal
usages, the young shoots of S. polyanthum were commonly
consumed as a fresh salad (ulam) whereas the mature
leaves were regularly added as a flavour enhancer in Malays’
cuisines.
With the popular use of S. polyanthum leaves, few
studies on its biological properties were carried out. Among
the findings, S. polyanthum leaves’ extracts were proven to
possess antibacterial activity against Staphylococcus aureus
[2], antifungal activities against Alternaria alternata and
Colletotrichum capsici [3], antinematodal activity against the
pine wood nematode, Bursaphelenchus xylophilus [4], anti-
tumor promoting activity [5], and antioxidant activity [6–9].
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Besides, S. polyanthum leaves extract is also noncytotoxic to
normal mammalian cell lines [9].
Despite its known biological effects, the phytochemical
constituents in the crude extracts of S. polyanthum leaves
were only preliminarily studied.The crude ethanolic extracts
of the leaves and the fruits of S. polyanthum contain ter-
penoids, phenols, tannins, flavonoids, and alkaloids [8].
Steroids were found in the crude ethanolic extract of the
leaves and the ripe fruits. Saponins were found in the unripe
fruits, whereas carbohydrates were present in both the ripe
and unripe fruits [8]. On the other hand, the chemical consti-
tuents of the essential oil from S. polyanthum leaves are exten-
sively studied. Dalimartha (2000) in [10] reported eugenol
as one of the compounds present in S. polyanthum leaves.
Eugenol, a phenolic compound abundantly found in Syzy-
gium family [11], has reputed ability as a vasorelaxant com-
pound that causes vasodilation in vitro [12–14] and reduces
blood pressure and heart rate of rats in vivo [15]. Other
major phytochemical constituents of the essential oil from S.
polyanthum leaves include cis-4-decenal, octanal, 𝛼-pinene,
farnesol, 𝛽-ocimene, and nonanal [16]. While using hexane
as solvent, the essential oil of S. polyanthum leaves contains
cis-4-decenal, octanal, 𝛼-pinene, farnesol, nerolidol, and
decanal at various percentages. Among the compounds, the
presence of 𝛼-pinene which belongs to terpenoid family is
notable since it was associated with hypotension in both the
nonanaesthetized [17] and the urethane-anaesthetized rats
[18]. Although these two compoundsmight correlate with the
proclaimed traditional use of S. polyanthum leaves as an anti-
hypertensive remedy, but these studied compounds were just
sparingly soluble in water. Thus, the alleged claim on anti-
hypertensive ability of the decoction of S. polyanthum leaves
still requires verification.
Therefore, the aim of this study was to elucidate the
effects of aqueous and residual methanolic extracts of S. poly-
anthum leaves on mean arterial (MAP), systolic (SBP), and
diastolic (DBP) blood pressure and heart rate (HR) of ana-
esthetized male Wistar-Kyoto (WKY) and spontaneously
hypertensive (SHR) rats. Instead of using noninvasive blood
pressure measurement method that requires prior warming
and restraining of the rats which significantly increased the
baseline blood pressure of SHR due to stress [19], the effects
of AESP and met-AESP were elucidated in this study in a
more calm, resting anaesthesia condition. Indeed, the inva-
sive measurement of blood pressure under anaesthesia was
widely used in determining hypotensive or antihypertensive
properties of plant extracts [20–23]. Besides, this study also
aims to elucidate the possible involvement of autonomic ner-
vous system (ANS) inmediating the hypotensive effects of the
extracts.
2. Materials and Methods
2.1. Reagents. Dimethylsulfoxide (DMSO) and 95% meth-
anol (v/v) were purchased from Merck, Malaysia. Hexam-
ethoniumbromide, isoproterenol hydrochloride, propranolol
hydrochloride, acetylcholine chloride, atropine sulphate,
phentolamine hydrochloride, methoxamine hydrochloride,
and N-𝜔-nitro-l arginine methyl ester (L-NAME) were
purchased from Sigma, USA. Sodium pentobarbital (Nem-
butal) was bought as an injectable solution (60mg/mL,
w/v) fromCeva-Sante Animale, France. Heparin (Heparinol-
5000, Malaysia) was bought from Ain Medicare Sdn. Bhd,
Malaysia.
2.2. Animals. Three- to five-month-old male normotensive
Wistar-Kyoto (WKY) and spontaneously hypertensive rats
(SHR) (280–350 g) were supplied by Animal Research and
Service Centre, Health Campus, Universiti Sains Malaysia.
The research methodology was approved by the Animal
Ethics Committee, Universiti Sains Malaysia (USM/Animal
Ethics Approval/2010/(59) (244)). These animals were kept
in standard rat cages and allowed to acclimatize for 7 days
in a standard environmental condition (25∘C with 60–70%
humidity) on a 12 hr light-dark cycle. Animals were given
standard rat pellet (Chipsi Classic Heimtierbett, Germany)
and tap water ad libitum.
2.3. PlantMaterial. S. polyanthum leaves were collected from
the District of Bachok, Kelantan, Malaysia, from March to
April 2010. The plant was identified by Dr. Richard Chung
from Forest Research Institute Malaysia (FRIM). The herbal
specimen (dried leaves) was deposited into FRIM herbarium
(sample number: PID-171011-10).
2.4. Preparation of Extracts and Drugs. Four kilograms of
S. polyanthum leaves was weighed using digital weighing
balance (A&DHV-60KGL, Columbia), washed with distilled
water, and dried in an incubator (Memmert GmbH +Co.KG,
Germany) at a preset temperature of 50∘C for 3 consecutive
days. The dried leaves (1.74 kg) were ground into powder
in a laboratory blender (WARING Commercial, USA) and
the filtrate was sieved off by mechanical siever (No. 35). For
extraction, 1.5 kg of the powdered sample was immersed in
15 L of distilled water and heated on hot plate (Erla EMS-HP-
700, Illinois) at 80–90∘C with continuous stirring for 30min.
The extract was then filtered through Whatman No. 41 filter
paper (Whatman Schleicher and Schuell, Malaysia) and then
lyophilized in freeze-dryer (ilShin, Korea). The lyophilized
sample (147.15 g) was designated as the aqueous extract of
S. polyanthum leaves (AESP). To extract the remaining less-
polar compounds from the residue of the aqueous extrac-
tion, 1.4 kg of the residue was extracted using 14 L of 95%
methanol (v/v) in Soxhlet apparatus (Favorit, Thailand) for
2 continuous cycles. The extract was then concentrated via
rotary evaporator (Heidolph Rotavac, Germany) and dried
in the incubator (Memmert GmbH + Co.KG, Germany) at a
preset temperature of 50∘C. The extract was then designated
as the methanolic extract of S. polyanthum leaves (met-
AESP) (26.04 g). AESP and met-AESP were finally kept in
an air-tight bottle and stored in a refrigerator (National NR-
B53FE, Malaysia) at 4∘C until use. AESP and met-AESP were
dissolved in 0.9% (w/v) normal saline but met-AESP was
further added with 5% (v/v) DMSO. AESP and met-AESP
were freshly prepared by dissolving the extracts in 1mL of
their respective vehicles. AESP andmet-AESP solutions (final
dose of 100mg/kg) were further diluted with their respective
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vehicles to achieve the doses of 70, 40, 30, 20, and 10mg/kg.
AESP and met-AESP solutions were then homogenized
using a homogenizer (Ultra-Turrax T25 Basic, Malaysia) at
24,000/min for 3min. All drugs were dissolved in 0.9% nor-
mal saline except for phentolamine hydrochloride which was
dissolved in 0.9% normal saline plus 5% dimethylsulfoxide
(DMSO).
2.5. Effects of Extracts on MAP, SBP, DBP, and HR of
Anaesthetized Rats. WKY (𝑛 = 5, each for AESP- and met-
AESP-treated group) and SHR (𝑛 = 5, each for AESP- and
met-AESP-treated group) were anaesthetized with 50mg/kg
sodium pentobarbital via intraperitoneal injection according
to previous studies [20, 22] before being placed on a thermally
controlled heating table (37±1∘C). Anaesthetic conditionwas
assessed by pinching the tail and the toe.The use of 50mg/kg
sodium pentobarbital was reported to not significantly affect
the baselines of blood pressure and heart rate of SHR [19], but
inWKY, only baseline of blood pressure was not significantly
affectedwhile the heart rate was increased [24] in comparison
with conscious rats. Indeed, several hypotensive studies
using similar anaesthetics scheme reported a nonsignificant
difference for the magnitude of hypotensive and bradycardic
effects between both anaesthetized and conscious WKY rats
[20–22]. Upon tracheotomy, an endotracheal polyethylene
tube was inserted into the incised trachea to prevent
airway obstruction. The left jugular vein was cannulated
for extracts’ injection and the right common carotid artery
was cannulated for MAP, SBP, DBP, and HR recordings
using MP30 BIOPAC acquisition system (BIOPAC Systems
Inc., USA) via pressure transducer (SS13L) and analyzed
using BIOPAC Student Lab Pro v3.6.7. After 20min of
equilibration period, 0.2mL of the respective vehicle was
intravenously administered as a negative control followed
by 0.2mL of AESP or met-AESP (10, 20, 30, 40, 70, and
100mg/kg). In between these doses, an additional 0.2mL of
heparinised (5 IU/mL) normal saline (0.9%, w/v) was flushed
intravenously to prevent intravascular blood clotting. MAP,
SBP, DBP, and HR responses were observed. From MAP,
SBP, DBP, and HR recordings, the changes in MAP (ΔMAP),
SBP (ΔSBP), (ΔDBP), and HR (ΔHR) from baseline values
were calculated and expressed in percentage as described
by Medeiros and colleagues [25] using the following form-
ula.
(MAP/SBP/DBP/HRbaseline −MAP/SBP/DBP/HRafter extracts administration)
MAP/SBP/DBP/HRbaseline
× 100. (1)
Time-course changes in MAP, SBP, DBP, and HR were also
recorded and analyzed onminute-to-minute basis for 20min.
The recording time was set to be 20min based on our pre-
liminary study that showed that the longest recovery timewas
17min.
2.6. Effects of Autonomic Ganglion, 𝛼-, 𝛽-Adrenergic, and
Cholinergic Receptors Blockage in MAP, SBP, DBP, and HR
of AnaesthetizedWKY. Pharmacological antagonistic studies
[15, 23] using blockers were performed on 5 different sets of
experiments. Specific ANS receptor antagonists such as hex-
amethonium bromide (10mg/kg), phentolamine hydrochlo-
ride (2mg/kg), propranolol hydrochloride (2mg/kg), and
atropine sulphate (2mg/kg)were used to block the autonomic
ganglion, 𝛼-adrenergic, 𝛽-adrenergic, and cholinergic recep-
tors, respectively. To investigate the role of nitric oxide, N-
𝜔-nitro-l arginine methyl ester, L-NAME (20mg/kg), was
used to block the endothelial nitric oxide synthase (eNOS)
enzyme. Specific agonists for 𝛼-adrenergic, 𝛽-adrenergic,
and cholinergic receptors such as methoxamine hydrochlo-
ride (50𝜇g/kg), isoproterenol hydrochloride (1.2 𝜇g/kg), and
acetylcholine chloride (5𝜇g/kg), respectively, were used as
positive controls to ensure sufficient blockages. In each of the
experiments, 100mg/kg AESP or met-AESP was introduced.
The dose was chosen based on our preliminary experiments
whereby only 100mg/kg AESP caused significant bradycar-
dia. To check for the involvement of autonomic ganglion
and eNOS enzyme blockages, these boluses of injections
were administered intravenously according to the following
sequence; (i) test dose, (ii) blocker, and (iii) test dose. In order
to check for the involvement of 𝛼-adrenergic, 𝛽-adrenergic,
and cholinergic receptors, the sequence of treatments was as
follows: (i) test dose, (ii) agonist, (iii) blocker, (iv) agonist, and
(v) test dose.
2.7. Statistical Analyses. MAP, SBP, DBP and HR were
expressed asmean ± standard deviation (SD). ED
50
values for
AESP- and met-AESP-induced reductions of MAP, SBP and
DBP were derived from nonlinear regression equation and
calculated using GraphPad PRISM version 5.01. Statistical
analyses were performed using similar software. One-way
ANOVA test was used to determine significant differences
between multiple doses, whereas repeated measures 2-way
ANOVA test was used to determine the differences between
the responses over time. By comparing the averaged readings
ofMAP, SBP,DBP, andHRupon extracts’ administrationwith
the initial baseline value every minute for 20min, recovery
time was then allotted when the averaged readings of MAP,
SBP, DBP, and HR were no longer significantly different as
compared to the initial baseline value. A post hoc Bonferroni
test was performed to compare the effects of the multiple
doses over time. For antagonistic study, paired 𝑡-test was
carried out. The value of 𝑃 less than 0.05 was considered to
be significant.
3. Results
3.1. Effects of AESP andMet-AESP onMAP, SBP, DBP, andHR.
Baselines of MAP, SBP, DBP, and HR for WKY before any
treatment were 134.53±10.72mmHg, 150.20±13.65mmHg,
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119.935 ± 9.27mmHg, and 298.88 ± 42.17 beats/min (𝑛 =
10). Baselines of MAP, SBP, DBP, and HR in SHR were
194.25 ± 8.75, 218.14 ± 11.15mmHg, 168.90 ± 11.89mmHg,
and 329.90±30.32 bpm (𝑛 = 10). Intravenous administrations
of 0.2mL vehicles for AESP (0.9% normal saline) and met-
AESP (0.9% normal saline + 5% DMSO) did not cause any
significant changes to baseline MAP, SBP, DBP, and HR
upon 20min observation period. As compared to negative
control, intravenous administrations of AESP bolus (0.2mL,
100mg/kg) caused significant changes to baseline MAP, SBP,
DBP, and HR (see Figures 1(a), 1(b), 1(c), and 1(d)) while met-
AESP bolus (0.2mL, 100mg/kg) caused significant changes
to baseline MAP, SBP, and DBP (see Figures 1(e), 1(f), and
1(g)), but not to baseline HR (see Figure 1(h)) upon 20min
observation period.
AESP from 20 to 100mg/kg induced significant dose-
dependent reductions of MAP (𝑃 < 0.001; see Figure 2(a)),
SBP (𝑃 < 0.01; see Figure 2(b)), and DBP (𝑃 < 0.05; see
Figure 2(c)) with only 100mg/kg AESP causing a significant
reduction of HR (𝑃 < 0.001; see Figure 4) in both WKY
and SHR. AESP-induced reduction of MAP in WKY was
significantly higher (𝑃 < 0.05) than in SHR at 30mg/kg
(see Figure 2(a)). AESP-induced reduction of SBP in WKY
was comparable to reduction in SHR (see Figure 2(b)). AESP-
induced reductions of DBP inWKYwere significantly higher
than in SHR at 30 (𝑃 < 0.01), 70 (𝑃 < 0.01), and 100mg/kg
(𝑃 < 0.01) (see Figure 2(c)).
Met-AESP from 40 to 100mg/kg induced significant (𝑃 <
0.05) dose-dependent reductions of MAP (𝑃 < 0.05, see
Figure 2(c)), SBP (𝑃 < 0.05; see Figure 2(d)) and DBP (𝑃 <
0.05; see Figure 2(e)) in WKY; whereas, in SHR, 30mg/kg to
100mg/kg met-AESP induced significant reductions of MAP
(𝑃 < 0.001; see Figure 2(d)), SBP (𝑃 < 0.001; see Figure 2(e))
and DBP (𝑃 < 0.001, see Figure 2(f)). Met-AESP-induced
reductions of MAP, SBP and DBP in SHR were significantly
higher than in WKY at 40 (𝑃 < 0.001, 𝑃 < 0.001, and
𝑃 < 0.001, resp.) and at 70mg/kg (𝑃 < 0.001, 𝑃 < 0.01, and
𝑃 < 0.01, resp.) (see Figures 2(d), 2(e), and 2(f)).
AESP-induced reductions of MAP, SBP, and DBP
were significantly higher than those of met-AESP-induced
hypotension in WKY at 40 (𝑃 < 0.01, 𝑃 < 0.001, and
𝑃 < 0.01, resp.) and at 70mg/kg (𝑃 < 0.01, 𝑃 < 0.001,
and 𝑃 < 0.05, resp.) (see Figures 3(a), 3(b), and 3(c)). Met-
AESP-induced reduction of MAP was significantly higher
than AESP-induced reduction of MAP in SHR at 70mg/kg
(𝑃 < 0.05) (see Figure 3(d)). Met-AESP-induced reduction of
SBP in SHR was comparable to AESP-induced reduction of
SBP in SHR (see Figure 3(e)). Met-AESP-induced reductions
of DBP were significantly higher than AESP-induced
reduction of DBP in SHR at 40mg/kg (𝑃 < 0.05) and
70mg/kg (𝑃 < 0.01) (see Figure 3(f)).
ED
50
value for AESP-induced reductions of MAP, SBP,
and DBP was lower in WKY (25.28 ± 2.33, 21.80 ± 2.34, and
26.67 ± 2.34, resp.) than in SHR (32.28 ± 2.53, 26.32 ± 2.52,
and 32.97 ± 2.58, resp.) (see Table 1). ED
50
values for met-
AESP-induced reduction of MAP, SBP and DBP were lower
in SHR (33.05 ± 2.34, 32.08 ± 2.36, and 32.25 ± 2.34, resp.)
than in WKY (54.58 ± 2.41, 63.83 ± 2.37, and 72.14 ± 2.43,
resp.). Overall, the ED
50
values for AESP-induced reductions
of MAP, SBP and DBP were lower than those for met-AESP
in WKY (see Table 1). The ED
50
values for AESP-induced
reductions of MAP and SBP were lower than ED
50
values for
met-AESP in SHR but not for DBP reduction (see Table 1).
Only 100mg/kg AESP caused reduction of HR in both
WKY and SHR. However, AESP-induced HR reductions in
both WKY and SHR were not significantly different (see
Figure 4).
3.2. Time-Course Changes in MAP, SBP, DBP, and HR by
AESP and Met-AESP. In terms of the onset time of action,
the maximal AESP-induced hypotension at all doses was
achieved within 0.5min after injection and formet-AESPwas
within 1.5min.
Generally, AESP-induced reductions of MAP, SBP, and
DBP recovered within 2–6min in WKY and within 1–4min
in SHR. The highest dose of AESP (100mg/kg) caused
reduction of HR that recovered within 17min in WKY and
5min in SHR (see Table 2). Met-AESP-induced reductions
of MAP, SBP and DBP recovered within 4–6min in WKY
and within 3–5min in SHR (see Table 2). Generally, AESP
recovered faster in SHR than in WKY. AESP also recovered
faster than met-AESP in SHR.
3.3. Effects of Autonomic Ganglion Receptors Blockage on
Changes in MAP, SBP, DBP and HR of Anaesthetized WKY.
Blockage of autonomic ganglion with 10mg/kg hexam-
ethonium bromide caused significant attenuation in AESP-
induced reductions of MAP, SBP, and DBP by 15.11± 10.01%
(𝑃 < 0.05), 34.89 ± 14.77% (𝑃 < 0.01) and 18.21 ±
10.10% (𝑃 < 0.01), respectively (see Figures 5(a), 5(b), and
5(c)). Similar blockages have also attenuated the met-AESP-
induced reductions of MAP, SBP, and DBP by 70.51± 10.84%
(𝑃 < 0.01), 51.79 ± 19.43% (𝑃 < 0.05) and 47.20 ± 23.90%
(𝑃 < 0.05), respectively (see Figures 5(a), 5(b), and 5(c)). The
bradycardic effect by 100mg/kg AESP was not significantly
changed (see Figure 5(d)).
3.4. Effects of 𝛼-Adrenergic Receptors Blockage on Changes
in MAP, SBP, DBP, and HR of Anaesthetized WKY. Phento-
lamine hydrochloride (2mg/kg) that significantly blocked the
increments of MAP, SBP, and DBP induced by the positive
control drug, methoxamine hydrochloride (50𝜇g/kg), by
95.13 ± 7.17% (𝑃 < 0.001), 91.18 ± 14.76% (𝑃 < 0.001)
and 87.23 ± 23.77 (𝑃 < 0.001) caused significant attenuations
in AESP-induced reductions of MAP, SBP, DBP, and HR by
40.86 ± 24.34% (𝑃 < 0.05), 67.09 ± 23.69% (𝑃 < 0.01),
52.98 ± 31.62% (𝑃 < 0.05), and 70.35 ± 19.54% (𝑃 < 0.05),
respectively (see Figures 6(a), 6(b), 6(c), and 6(d)). In another
set of experiments, phentolamine hydrochloride (2mg/kg)
that significantly abolished the increment of MAP, SBP and
DBP induced by the positive control drug, methoxamine
hydrochloride (50 𝜇g/kg), by 80.80 ± 18.61% (𝑃 < 0.001),
68.16 ± 27.43% (𝑃 < 0.001), and 58.44 ± 38.61% (𝑃 < 0.001)
did not significantly affect met-AESP-induced reductions of
MAP, SBP, and DBP (see Figures 6(a), 6(b), and 6(c)).
3.5. Effects of 𝛽-Adrenergic Receptors Blockage on Changes in
MAP, SBP, DBP, and HR of Anaesthetized WKY. Propranolol
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Figure 1: Tracings represent the effects of 0.9% normal saline as opposed to 100mg/kgAESP on (a)MAP, (b) SBP, (c) DBP, and (d)HR and the
effects of 0.9% normal saline plus 5% DMSO as opposed to 100mg/kg met-AESP on (e) MAP, (f) SBP, (g) DBP, and (h) HR. MAP: recorded
mean arterial blood pressure in millimetres of mercury, SBP: recorded systolic blood pressure in millimetres of mercury, DBP: recorded
diastolic blood pressure in millimetres of mercury, HR: recorded heart rate in beats per minute, AESP: aqueous extract of S. polyanthum
leaves, met-AESP: residual methanolic extract of S. polyanthum leaves, SHR: spontaneously hypertensive rats, WKY:Wistar-Kyoto rats, NaCl:
sodium chloride, DMSO: dimethylsulfoxide.
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Figure 2: Effects of AESP on (a) MAP, (b) SBP, (c) DBP and effects of met-AESP on (d) MAP, (e) SBP, and (f) DBP of both WKY and SHR.
ΔMAP/SBP/DBP: changes of MAP/SBP/DBP from baseline (expressed as mean percentage ± SD, 𝑛 = 5 animals per group), AESP: aqueous
extract of S. polyanthum leaves, met-AESP: residual methanolic extract of S. polyanthum leaves,WKY:Wistar-Kyoto rats, SHR: spontaneously
hypertensive rats. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001.
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Figure 3: Effects of AESP and met-AESP on (a) MAP, (b) SBP, and (c) DBP of WKY and on (d) MAP, (e) SBP, (f) DBP of SHR.
ΔMAP/SBP/DBP: changes of MAP/SBP/DBP from baseline (expressed as mean percentage ± SD, 𝑛 = 5 animals per group), AESP: aqueous
extract of S. polyanthum leaves, met-AESP: residual methanolic extract of S. polyanthum leaves,WKY:Wistar-Kyoto rats, SHR: spontaneously
hypertensive rats. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001.
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Table 1: ED50 values of AESP and met-AESP-induced hypotension.
Model of rats
ED50 values for the induced hypotension
AESP Met-AESP
MAP SBP DBP MAP SBP DBP
WKY 25.28 ± 2.33 21.80 ± 2.34 26.67 ± 2.34 54.58 ± 2.41 63.83 ± 2.37 72.14 ± 2.43
SHR 32.28 ± 2.53 26.32 ± 2.52 32.97 ± 2.58 33.05 ± 2.34 32.08 ± 2.36 32.25 ± 2.34
ED50 value: mean of dose ± SD that causes 50% maximal reduction of MAP, SBP, and DBP, calculated by GraphPad PRISM version 5.01 software by using
nonlinear regression equation, MAP: mean arterial blood pressure, SBP: systolic blood pressure, DBP: diastolic blood pressure, AESP: aqueous extract of S.
polyanthum leaves, met-AESP: residual methanolic extract of S. polyanthum leaves, WKY: Wistar-Kyoto rats, SHR: spontaneously hypertensive rats.
Table 2: Recovery time (in minutes) for 20, 30, 40, 70, and 100mg/kg AESP and met-AESP in WKY and SHR.
Recovery time (min)
Dose (mg/kg) AESP Met-AESP
MAP SBP DBP HR MAP SBP DBP HR
20 WKY 2 2 2 n.a n.a n.a n.a n.a
SHR 1 1 2 n.a n.a n.a n.a n.a
30 WKY 3 3 3 n.a n.a n.a n.a n.a
SHR 1 1 2 n.a 3 3 4 n.a
40 WKY 3 3 3 n.a 4 4 4 n.a
SHR 2 2 2 n.a 4 4 4 n.a
70 WKY 4 4 4 n.a 4 4 4 n.a
SHR 2 2 2 n.a 4 5 6 n.a
100 WKY 5 6 6 17 5 6 5 n.a
SHR 3 4 4 5 4 4 5 n.a
Recovery time: the time when the averaged readings of MAP, SBP, DBP, and HRwere no longer significantly different as compared to the initial baseline values.
MAP: recorded mean arterial blood pressure in millimetres of mercury, HR: recorded heart rate in beats per minute, AESP: aqueous extract of S. polyanthum
leaves, met-AESP: residual methanolic extract of S. polyanthum leaves, WKY: Wistar-Kyoto rats, SHR: spontaneously hypertensive rats, n.a: there were no
changes observed in the baselines of MAP, SBP, DBP, and HR upon administration of the respective doses.
hydrochloride (2mg/kg) that significantly blocked the
induced-reductions of MAP, SBP, and DBP by the positive
control drug, isoproterenol hydrochloride (1.2 𝜇g/kg), by
85.52 ± 7.17% (𝑃 < 0.001), 76.17 ± 21.09% (𝑃 < 0.01),
and 86.44 ± 9.90% (𝑃 < 0.001) did not significantly affect
AESP-induced reductions of MAP, SBP, DBP, and HR (see
Figures 7(a), 7(b), and 7(c)). In another set of experiments,
propranolol hydrochloride (2mg/kg) that significantly
blocked the induced-reductions of MAP, SBP, and DBP
by the positive control drug, isoproterenol hydrochloride
(1.2 𝜇g/kg), by 80.30 ± 14.03% (𝑃 < 0.01), 73.63 ± 21.17%
(𝑃 < 0.05), and 86.12 ± 10.18% (𝑃 < 0.01) also caused
significant attenuations on met-AESP-induced reductions
of MAP, SBP, and DBP by 39.27 ± 18.72% (𝑃 < 0.01),
33.87 ± 24.94% (𝑃 < 0.05), and 37.86 16.98% (𝑃 < 0.01),
respectively (see Figures 7(a), 7(b), and 7(c)).
3.6. Effects of Cholinergic Receptors Blockage on Changes in
MAP, SBP, DBP, and HR of Anaesthetized WKY. Atropine
sulphate (2mg/kg) that significantly blocked the reductions
of MAP, SBP, and DBP induced by the positive control drug,
acetylcholine chloride (5𝜇g/kg), by 85.77 ± 6.19% (𝑃 <
0.001), 96.07 ± 3.85% (𝑃 < 0.001), and 94.35 ± 4.76%
(𝑃 < 0.001) did not significantly affect AESP-induced
reductions of MAP, SBP, DBP and HR (see Figures 8(a),
8(b), 8(c), and 8(d)). In another set of experiments, atropine
sulphate (2mg/kg) that significantly blocked the reductions
of MAP, SBP, and DBP induced by the positive control drug,
acetylcholine chloride (5𝜇g/kg), by 83.71 ± 10.86% (𝑃 <
0.001), 94.78 ± 6.65% (𝑃 < 0.001), and 96.02 ± 7.68%
(𝑃 < 0.001) also attenuated met-AESP-induced hypotension
by 50.62 ± 29.65% (𝑃 < 0.01), 41.46 ± 28.47% (𝑃 < 0.01) and
42.68±28.22% (𝑃 < 0.01), respectively (see Figures 8(a), 8(b),
and 8(c)).
3.7. Effects of eNOS Enzyme Blockage on Changes inMAP, SBP,
DBP, and HR of AnaesthetizedWKY. Blockage of endothelial
nitric oxide synthase, eNOS, with 20mg/kg L-NAME caused
significant attenuation in met-AESP-induced reductions of
MAP, SBP, and DBP by 75.38 ± 19.32% (𝑃 < 0.001) 69.63 ±
19.79% (𝑃 < 0.001) and 75.38 ± 19.32% (𝑃 < 0.001) but not
in AESP-induced reductions of MAP, SBP, DBP, and HR (see
Figures 9(a), 9(b), 9(c), and 9(d)).
4. Discussion
This study has shown that both intravenous injections
of AESP and met-AESP boluses induced significant dose-
dependent hypotension while only the highest dose of AESP
caused significant bradycardia. The occurrence of bradycar-
dia, found to be accompanying the hypotensive effect of
AESP, was common in few other ethnomedicinal plants such
as Tacca integrifolia (Ker-Gawl). [26], Musanga cecropioides
[27], and Sida cordifolia [25]. Nevertheless, there are some
Evidence-Based Complementary and Alternative Medicine 9
−20
−15
−10
−5
0
WKY SHR
Different model of rats
Δ
H
R 
(%
)
Figure 4: Effects of intravenous administrations of 100mg/kg AESP
on the heart rate of WKY and SHR. ΔHR: changes of heart rate
from baseline (expressed as mean percentage ± SD), AESP: aqueous
extract of S. polyanthum leaves, WKY: Wistar-Kyoto rats, SHR:
spontaneously hypertensive rats.
other ethnomedicinal plants such asAndrographis paniculata
[23, 28] andBacopamonnieri [29], elicited hypotensive effects
without significant bradycardia as observed during met-
AESP-induced hypotension. Besides the appearance of brady-
cardia for AESP, AESP and met-AESP differed in terms of
onset time and sustainability of its action. The onset time for
AESP to achievemaximal hypotensionwas faster than that for
met-AESP in both WKY and SHR. AESP-induced hypoten-
sion was less sustained than met-AESP-induced hypotension
in SHR. This may indicate different composition of active
constituent(s) that perhaps acted on different pathways in
mediating the hypotensive effects by both extracts. This
study also showed that AESP-induced hypotension was more
potent inWKYwhereby it exhibited a comparable potency in
SHR as compared to met-AESP-induced hypotension.
This study has shown that both extracts reduced MAP,
SBP, and DBP of bothWKY and SHR. However, the recovery
time for AESP-induced hypotension and bradycardia was
shorter in SHR as compared to inWKY.This can be explained
by the preexistence of sympathetic overactivity in SHR as the
over activity of sympathetic system in turn might cause a
greater reflex pressor response to return the MAP, SBP, DBP,
and HR levels to the baseline in SHR. This phenomenon is
possible due to an altered number of adrenergic receptors or
change in its responsiveness in SHR [30].
Further pharmacological antagonistic studies were then
performed to elucidate the postulation that both extracts
acted via different mechanism(s) of actions. Since the recep-
tors of ANS are involved in sympathetic and parasympathetic
controls of blood pressure and heart rate, their effects were
further examined.
In this study, autonomic ganglion blockage was achieved
by addition of hexamethonium, a nicotinic receptors block-
ing agent which blocks ion channels of the autonomic ganglia
resulting in a blockage of the outputs of the sympathetic
and parasympathetic pathways [31]. Since autonomic gan-
glion blockage had attenuated partially the AESP-induced
hypotension, it might indicate a partial involvement of
ANS in regulating its actions. Further blockages of the two
peripheral receptors in ANS (cholinergic and 𝛽-adrenergic
receptors) with their respective antagonists, propranolol
and atropine, did not significantly affect neither AESP-
induced hypotension nor its bradycardic effect. However,
blockage of 𝛼-adrenergic receptors with phentolamine, a
competitive blocker of 𝛼
1
- and 𝛼
2
-adrenergic receptors, had
partially attenuated AESP-induced hypotension and brady-
cardia. Hence, it is suggested that AESP-induced hypotension
and bradycardia in this study were partially acted via ANS,
mediated by 𝛼-adrenergic receptors’ pathways. It is known
that 𝛼
1
-adrenergic receptor mediates vasoconstriction. On
the other hand, 𝛼
2
-receptors play a prominent role in lower-
ing blood pressure by inhibiting the synaptic release of neu-
rotransmitter that mediates the renin production [32]. Alpha
2-adrenergic receptors stimulation also modulates vagally-
induced baroreflex bradycardia [33]. Besides, hypotension
with accompanying bradycardia is a common effect of 𝛼
2
-
agonists such as clonidine, guanfacine, and 𝛼-methyldopa
[33, 34]. Thus, it is plausible to suggest that AESP-induced
hypotension was partially mediated by the 𝛼
2
-receptors.
As for met-AESP, blockage of autonomic ganglion signif-
icantly attenuated its hypotensive effect which may suggest
that its action was primarily mediated via ANS. Blockages
of the peripheral 𝛽-adrenergic receptors with propranolol,
a nonselective 𝛽-adrenergic receptors’ blocker [35], caused
a significant attenuation in met-AESP-induced hypotension.
Hence, it is suggested that met-AESP partially acted via 𝛽-
adrenergic receptors of the ANS. Among the 𝛽-adrenergic
receptors’ subtypes, 𝛽
1
subtype is involved in increasing the
blood pressure and heart rate while 𝛽
3
subtype was involved
in lipolysis and not related to the regulation of blood pressure
[36]. Thus, it is suggested that 𝛽
2
subtype receptor which is
responsible for smooth vessel relaxation [37] was involved in
mediating hypotensive effect of met-AESP. Blockages of the
peripheral muscarinic acetylcholine receptors with atropine,
a competitive muscarinic acetylcholine receptors’ blocker
[38], also caused significant attenuations in met-AESP-
induced hypotension. Hence, it is also suggested that, besides
𝛽-adrenergic receptors, met-AESP-induced hypotension was
also partially mediated via muscarinic acetylcholine recep-
tors. Moreover, the degree of attenuation by atropine was
much greater than that by propranolol. Hence, it is suggested
that met-AESP-induced hypotension was predominant on
muscarinic acetylcholine receptor. Muscarinic acetylcholine
receptor subtypes include M
1
, M
2
, M
3
, M
4
, and M
5
. M
1
subtype is present in gastric parietal cells whereasM
4
andM
5
subtypes are not being described in blood vessels.M
2
subtype
may cause reduction of the cardiac output, blood pressure,
and HR as a result of the decrement of firing rate at the
sinoatrial node in the heart [39].Thus, this subtype is unlikely
to be involved since met-AESP did not cause any significant
reduction of the HR. Therefore, it is suggested that the M
3
subtype was possibly involved since its activation causes
endothelium-dependent vasodilatation [40]. This study also
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Figure 5: Effects of autonomic ganglion receptors’ blockages on changes in (a) MAP, (b) SBP, (c) DBP, and (d) heart rate by various
treatments in WKY rats (𝑛 = 5). Hexa: 10mg/kg hexamethonium bromide, ΔMAP/SBP/DBP/HR: changes of MAP/SBP/DBP/HR from
baseline (expressed as mean percentage ± SD), AESP: aqueous extract of S. polyanthum leaves, met-AESP: residual methanolic extract of S.
polyanthum leaves, WKY: Wistar-Kyoto rats, SHR: spontaneously hypertensive rats. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01.
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Figure 6: Effects of 𝛼-adrenergic receptors’ blockage on changes in (a) MAP, (b) SBP, (c) DBP, and (d) HR by various treatments in WKY
rats (𝑛 = 5). Phento: 2mg/kg phentolamine hydrochloride, Methox: 50𝜇g/kg methoxamine hydrochloride, ΔMAP/SBP/DBP: changes of
MAP/SBP/DBP/HR from baseline (expressed as mean percentage ± SD), AESP: aqueous extract of S. polyanthum leaves, met-AESP: residual
methanolic extract of S. polyanthum leaves, WKY: Wistar-Kyoto rats, SHR: spontaneously hypertensive rats. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and
∗∗∗
𝑃 < 0.001.
showed that the action of met-AESP on ANS was less specific
as compared to AESP.
Beta-2-adrenergic and M
3
-muscarinic acetylcholine
receptors that are suggested to mediate met-AESP-induced
hypotension are associated with endothelium-dependent
vasodilatation or relaxation via increased synthesis of nitric
oxide [37, 40, 41]. Therefore, another antagonistic study
using L-NAME, a blocker of endothelial nitric oxide syn-
thase (eNOS), was performed. It is found that met-AESP-
induced hypotension was attenuated after blockage of eNOS
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Figure 7: Effects of 𝛽-adrenergic receptors’ blockage on changes in (a) MAP, (b) SBP, (c) DBP, and (d) HR by various treatments in
WKY rats (𝑛 = 5). Prop: 2mg/kg propranolol hydrochloride, Isop: 1.2 𝜇g/kg isoproterenol hydrochloride, ΔMAP/SBP/DBP/HR: changes of
MAP/SBP/DBP/HR from baseline (expressed as mean percentage ± SD), AESP: aqueous extract of S. polyanthum leaves, met-AESP: residual
methanolic extract of S. polyanthum leaves, WKY: Wistar-Kyoto rats, SHR: spontaneously hypertensive rats. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and
∗∗∗
𝑃 < 0.001.
while AESP-induced hypotension and bradycardia were
not significantly attenuated after blockage of eNOS. These
findings may support the suggestion of the partial involve-
ment of 𝛽
2
-adrenergic and M
3
-muscarinic acetylcholine
receptors in mediating met-AESP-induced hypotension.
Besides, these findings may also suggest that AESP-induced
hypotension did not involve direct nitric oxide generation.
Taken together, this studymay serve as a preliminary veri-
fication for the traditional claim of using S. polyanthum leaves
as a treatment of hypertension. The findings demonstrated
that AESP-induced hypotension was more potent than met-
AESP in WKY but both were comparably potent in SHR.
AESP acted faster in both WKY and SHR. AESP exhibited
comparable sustenance as met-AESP in WKY but it was less
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Figure 8: Effects of cholinergic receptors blockage on changes in (a) MAP, (b) SBP, (c) DBP, and (d) HR by various treatments in WKY
rats (𝑛 = 5). Atr: 2mg/kg atropine sulphate, Ach: 5 𝜇g/kg acetylcholine chloride. ΔMAP/SBP/DBP/HR: changes of MAP/SBP/DBP/HR from
baseline (expressed as mean percentage ± SD), AESP: aqueous extract of S. polyanthum leaves, met-AESP: residual methanolic extract of S.
polyanthum leaves, WKY: Wistar-Kyoto rats, SHR: spontaneously hypertensive rats. ∗∗𝑃 < 0.01 and ∗∗∗𝑃 < 0.001.
sustained in SHR. ANS partially mediates AESP actions via
𝛼-receptors and met-AESP via 𝛽-adrenergic and muscarinic
acetylcholine receptors through NO generation. However,
further works using much more subtype-specific antagonists
should be done for much more comprehensive verification.
Further studies are also warranted to investigate the active
compound(s) in AESP and met-AESP responsible for their
hypotensive effects.
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